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The transcription factor Sox2 is a master regulator that maintains stemness in embryonic stem cells and
neural stem cells. Using elegant lineage tracing strategies and genetic reporter mouse models, two studies
(one of which is by Vanner and colleagues in this issue of Cancer Cell) now demonstrate that rare Sox2-
expressing cells are the founding cancer stem cell population driving tumor initiation and therapy resistance.Sox2 is widely regarded as a key founding
member of the cohort of core transcrip-
tion regulators that controls pluripotency
and self-renewal in embryonic stem cells
and maintains the stemness of neural
stem cells (Gonzales and Ng, 2011; Sar-
kar and Hochedlinger, 2013). The origins
of cancer have been proposed to be
associated with the aberrant reactivation
of embryonic developmental or stem cell
programs within normal tissues (Wong
et al., 2008), but evidence supporting
this notion has not been forthcoming.
The idea that tumor-propagating cells
(hereafter referred as cancer stem cells
[CSCs]) share an imprint of embryonic or
stem cell origin is an attractive notion
that illustrates the conservation of stem-
ness programs in neoplasia.
Cancer stem cells are key drivers of
malignancy and are responsible for tumor
initiation, growth, and, quite possibly,
spawning metastases (Li et al., 2007; Val-
ent et al., 2012). In functional assays,
these rare cells are defined as being
able to initiate tumors in immunodeficient
or syngeneic mice when transplanted at
limiting dilution numbers; the resulting
tumors should, by these criteria, reca-
pitulate the complex organization and
histopathology of the original tumors
from which these cells were isolated (Val-
ent et al., 2012). The existence of CSCs
within heterogeneous tumors has pro-
found implications for cancer therapy.
Experimental observations suggest that
conventional chemotherapeutic agents
and radiation treatment often can effi-ciently eliminate the bulk of cells within
tumors, but, in many instances, leave
behind residues of therapy-resistant
CSCs that thereafter promote tumor re-
growth (Chen et al., 2012; Meacham and
Morrison, 2013). This results in clinical re-
lapses at primary or metastatic sites and
thereby contributes to patient mortality.
Defining the molecular architecture of
cancer stem-like cells, coupled with an
understanding of their preferential sensi-
tivity to specific targeted therapeutic
agents may therefore provide avenues
for the rational design of cancer treatment
regimes that target both CSCs and bulk
tumor cells in human patients.
While there has been considerable
debate on the creation and existence of
CSCs in physiological host settings,
more recent lineage tracing studies have
unequivocally demonstrated their exis-
tence in intestinal adenomas, skin squa-
mous cell carcinomas, and glioblastomas
using defined genetic mouse models
(Chen et al., 2012; Driessens et al., 2012;
Schepers et al., 2012). Until now, how-
ever, the phenotypic nature and molecu-
lar signatures associated with CSCs
during the onset of neoplasia have not
been clearly defined.
In this issue of Cancer Cell (Vanner
et al., 2014) and in Nature (Boumahdi
et al., 2014), two groups demonstrated
that Sox2-expressing (Sox2+) cells serve
as the founding population that generate
tumor growth, and give rise to the diver-
sity of differentiated cell progenies in
different cancer types (Figure 1). In theCancer Cstudy by Vanner et al. (2014), the authors
found quiescent Sox2+ cells to be respon-
sible for propagating medulloblastoma.
They utilized a Ptch1+/ (Ptc) mouse
model to recapitulate the sonic hedgehog
(SHH)-driven class of human medullo-
blastomas, which accounts for 30% of
these malignancies. In these Ptc tumors,
Sox2+ cells were indeed rare and, through
pulse-chase label analyses, were shown
to remain quiescent or slow cycling. By
contrast, doublecortin-positive (DCX+)
progenitor cells were rapidly cycling and
gave rise to well-differentiated neuronal
nuclei-positive (NeuN+) cells that were
short lived.
To functionally test the ability of Sox2+
cells in propagating the malignancy,
the Sox2-GFP reporter was crossed into
Ptc medulloblastoma mice. Sox2-GFP+
cells isolated from the resultant tumors
were indeed capable of self-renewal
in colony-forming assays in vitro and
robustly propagated tumors in orthotopic
sites when transplanted into immuno-
deficient mice at limiting dilutions,
whereas far larger numbers of Sox2 cells
lacked these characteristics. The gold
standard for demonstrating the hierar-
chical nature of cancer malignancies
is through genetic lineage tracing. Here,
the authors introduced a tamoxifen-
inducible Cre recombinase, driven by
the endogenous Sox2 promoter, and a
Cre-activated tdTomato fluorescent re-
porter into Ptc medulloblastoma mice.
Exposure of these mice to tamoxifen
initially labeled rare tdTomato+ Sox2+ell 26, July 14, 2014 ª2014 Elsevier Inc. 3
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Figure 1. Sox2 Expression Underlies Cancer Stem Cell Function
In two distinct mouse cancer models, Sox2+ cells initiate tumor growth and spawn differentiated cell lin-
eages that recapitulate primary tumor composition. In medulloblastoma, Sox2+ cells are quiescent and, in
lineage tracing experiments, found to be chemotherapy-resistant, thus promoting tumor recurrence.
Conditional deletion of Sox2 from the epidermis in squamous cell carcinoma triggers tumor regression,
and Sox2+ cells are responsible for tumor initiation and growth. Tumor propagation by the founder cells
appears to recapitulate embryonic and stem cell differentiation programs that operate within normal
tissues.
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subsequently spawned tdTomato+ Sox2
bulk tumor cells expressing markers
of neuronal and glial differentiation, thus
elegantly demonstrating the nature of
CSC differentiation.
Drawing parallels between therapy
resistance in human and mouse malig-
nancies, treatment of medulloblastomas
in Ptc mice with an antimitotic drug
(cytarabine) or an SHH pathway inhibitor
(vismodegib) resulted in residual tumors
that were enriched in Sox2+ cells, indi-
cating that these cells were likely to
contribute toward tumor relapse. Hence,
the ability of Sox2+ CSCs to remain quies-
cent and resist antimitotic drugs provides
a survival advantage under strong selec-
tion pressure and points to at least one
mode by which CSCs are protected
from certain cancer therapies.
The observation that Sox2+ cells lay
at the apex of the stem cell and CSC4 Cancer Cell 26, July 14, 2014 ª2014 Elsevihierarchy is further illustrated in skin
squamous cell carcinoma (SCC), which
is the second most frequent skin cancer.
In mice, skin SCC progression is modeled
through the topical application of carcino-
gens, DMBA and TPA, on the epidermis,
progressively generating hyperplasia,
papilloma, and finally SCC over the
course of several weeks. Blanpain and
his group had previously discovered
squamous skin tumors arose from a
restricted clonal pool of CSCs using a
mouse model, but a genetic marker that
could identify these cells was not defined
(Driessens et al., 2012). Here, using Sox2-
GFP knock-in mice, Boumahdi et al.
(2014) began to observe the appearance
of Sox2-GFP+ cells, whichwere otherwise
absent from the normal epidermis, in
hyperplastic lesions that increased in
frequency in papilloma and SCC. Unlike
SCCs that arise from other tissues where
Sox2 is frequently genetically amplified,er Inc.murine and human skin tumors do not
contain such genetic amplification. In
this case, it was demonstrated here the
Sox2 promoter was indeed epigenetically
silenced in normal epidermis but became
transcriptionally activated during tumor
initiation. Hence, it appears plausible
that the aberrant activation of Sox2 within
a group of transformed cells causes
them to shift toward a CSC phenotype,
highlighting the highly plastic nature of
neoplastic cells.
Consistent with Vanner et al. (2014),
transplantation of Sox2-GFP+ cells de-
rived from invasive SCC into immunode-
ficient mice at limiting dilution numbers
resulted in tumors that could be serially
transplanted, whereas Sox2-GFP cells
were deficient in this regard. Sox2-
GFP+ cells produced tumors that con-
tained Sox2-GFP carcinoma cells,
lending support to a hierarchical CSC
model. Furthermore, Sox2+ cells were
enriched during serial transplantation of
primary tumor cells to form secondary
tumors; this indicates cancer therapies
may, in some instances, increase the
representation of CSCs in recurring tu-
mors and hasten disease progression.
Remarkably, conditional deletion of Sox2
from the epidermis dramatically delayed
tumor onset and lesion numbers induced
by carcinogen exposure, thereby pro-
viding direct support for Sox2 as being
functionally critical for conferring tumor
initiation potential in skin SCCs and not
merely behave as a bystander stemness
marker.
The discovery of Sox2 as a functional
CSC marker in medulloblastoma and
squamous cell carcinoma provides a
unique window of opportunity to dissect
molecular signatures associated with
CSCs and to interrogate differentiation
programs that operate within these cells.
In medulloblastoma, Sox2+ cell-driven
tumors followed a neurogenic differen-
tiation program that mirrored adult and
developmental neurogenesis. Likewise,
Sox2+ cells within SCCs appeared to re-
activate a genetic program that is present
in the embryonic epidermis, thus reflect-
ing the recapitulation of a developmental
program in CSCs.
The finding that Sox2+ cells are the
roots of tumors in two distinct types of
cancers is striking; this leaves open a
possibility that Sox2 might mastermind
the tumor initiating potential of cells found
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Previewswithin other malignancies. Quite possibly,
one might uncover other embryonic regu-
lators that also become aberrantly reacti-
vated. Although quiescence serves as
a protective mechanism for Sox2+ tumor
cells, it remains unclear if they also
possess additional strategies that protect
them against insults from other therapeu-
tic agents that act in a different manner.
More comprehensive interrogation of
molecular hallmarks attributed to CSCs
will likely reveal vulnerabilities that could
be targeted with CSC-specific therapies.
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Profound metabolic differences between cancer cells and fibroblasts promote tumorigenesis. A study by
Valencia and colleagues in this issue of Cancer Cell supports this assertion. They observed that metabolic
asymmetry in prostate tumors drives aggressive disease with high p62 in anabolic cancer cells, but loss of
p62 in catabolic fibroblasts.Recent advances in tumor metabolism
have revealed that there are dra-
matic metabolic differences between the
distinct cell types that compose a tumor.
A newly described phenomenon is that
cancer cells metabolically reprogram fi-
broblasts resulting in ‘‘metabolic asym-
metry’’ between cancer cells and fibro-
blasts that promotes tumor growth.
In asymmetric tumor metabolism, can-
cer cells are anabolic due to catabolic
tumor fibroblasts (Martinez-Outschoorn
et al., 2014). Initial studies on meta-
bolic asymmetry were performed in hu-
man breast cancer, but it has also beendemonstrated in ovarian cancer, head
and neck cancer, and lymphomas. It is
now well recognized that metabolic trans-
formation of fibroblasts with increased
catabolism occurs via inflammation and
high levels of reactive oxygen species
(ROS) acting as the second messenger,
and these are critical factors for initiating
tumorigenesis, cancer progression, and
distant metastasis. A new elegant study
inCancer Cell by Valencia et al. (2014) crit-
ically enhances our understanding of this
emerging paradigm in prostate cancer.
Fibroblast catabolic processes such
as autophagy provide the high-energycatabolites (such as L-lactate, ketones,
and glutamine) to the anabolic cancer
cells. Asymmetry of metabolism also oc-
curs between cancer cells and tissues at
a distance, with increased fatty acid gen-
eration in adipose tissue and catabolism
in muscle, in melanoma, and lung cancer
models (Das et al., 2011). Metabolic
asymmetry with catabolic cells sup-
porting anabolic cells can even occur
between different carcinoma cell popula-
tions within a single tumor (Sonveaux
et al., 2008). These examples show that
metabolic asymmetry and energy transfer
occurs in human tumors and that cancerell 26, July 14, 2014 ª2014 Elsevier Inc. 5
